Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/1/2020
SIETES contiene 92881 citas

 
 
<< anterior 21 a 40 de 367 siguiente >>
Presentar resultados
Seleccionar todas
21.Tiene citas relacionadas
Etminan M, Brophy JM. Antibiotics and sudden death in adults taking renin-angiotensin system blockers. BMJ 2014;349:g6242. [Ref.ID 98356]
22. Cita con resumen
Anónimo. Télithromycine: bilan des effets indésirables. Prescrire 2014;34:512-5. [Ref.ID 98075]
23. Cita con resumen
Weeke P, Jensen A, Folke F, Gislason GH, Fosbol EL, Wissenberg M, Lippert FK, Christensen EF, Nielsen SL, Holm E, Kanters JK, Poulsen HE, Kober L, Torp-Pedersen C. Antipsychotics and associated risk of out-of-hospital cardiac arrest. Clin Pharmacol Ther 2014;96:490-7. [Ref.ID 97924]
24. Cita con resumen
Anónimo. Sorafenib (Nexavar) for thyroid cancer. Med Lett Drugs Ther 2014;56:43-4. [Ref.ID 97918]
26.Enlace a cita original
Isbister GK, Page CB. Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice. Br J Clin Pharmacol 2013;76:48-57. [Ref.ID 95802]
27.Enlace a cita original Cita con resumen
Celaya Lecea MC, Martínez Basterra J. Medicamentos y prolongación del intervalo QT. Boletín de Información Farmacoterapéutica de Navarra 2013;21:1-7. [Ref.ID 95707]
28. Cita con resumen
Poluzzi E, Raschi E, Koci A, Moretti U, Spina E, Behr ER, Sturkenboom M, De Ponti F. Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database. Drug Saf 2013;36:467-79. [Ref.ID 95666]
29. Cita con resumen
Kao D, Bartelson BB, Khatri V, Dart R, Mehler PS, Katz D, Krantz MJ. Trends in reporting methadone-associated cardiac arrhythmia, 1997-2011: an analysis of registry data. Ann Intern Med 2013;158:735-40. [Ref.ID 95456]
30. Cita con resumen
Zivin K, Pfeiffer PN, Bohnert ASB, Ganoczy D, Blow FC, Nallamothu BK, Kales HC. Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg . Am J Psychiatry 2013;170:642-50. [Ref.ID 95452]
31. Cita con resumen
Haugaa KH, Bos JM, Tarrell RF, Morlan BW, Caraballo PJ, Ackerman MJ. Institution-wide QT alert system identifies patients with a high risk of mortality. Mayo Clin Proc 2013;88:315-25. [Ref.ID 95349]
32.Enlace a cita original Cita con resumen
Cooke MJ, Waring WS. Citalopram and cardiac toxicity. Eur J Clin Pharmacol 2013;69:755-60. [Ref.ID 95191]
34. Cita con resumen
Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, Erb JL, Churchill SE, Kohane IS, Iosifescu DV, Smoller JW, Perlis RH. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ 2013;346:15. [Ref.ID 94930]
35. Cita con resumen
Loghin C, Haber H, Beasley Jr CM, Kothare PA, Kauffman L, April J, Jin L, Allen AJ, Mitchell MI. Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers. Br J Clin Pharmacol 2013;75:549-64. [Ref.ID 94857]
36. Cita con resumen
Purhonen M, Koponen H, Tiihonen J, Tanskanen A. Outcome of patients after market withdrawal of thioridazine: a retrospective analysis in a nationwide cohort. Pharmacoepidemiol Drug Saf 2012;21:1227-31. [Ref.ID 93992]
37. Cita con resumen
Anónimo. Citalopram (Celexa) and QT interval prolongation. Med Lett Drugs Ther 2012;43:71-2. [Ref.ID 93704]
38.Tiene citas relacionadas
Ray WA, Murray KT, Stein CM. Azithromycin and the risk of cardiovascular death. Author/editor response. N Engl J Med 2012;367:775. [Ref.ID 93628]
39.Tiene citas relacionadas
dos Santos RP, Kuchenbecker R. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;367:774. [Ref.ID 93627]
40.Tiene citas relacionadas
Koga T, Imaoka H. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;367:773-4. [Ref.ID 93626]
Seleccionar todas
 
<< anterior 21 a 40 de 367 siguiente >>